Company Filing History:
Years Active: 2023
Title: The Innovations of Sae Hyung Lee
Introduction
Sae Hyung Lee is a notable inventor based in Seongnam-si, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic agents. His work focuses on improving treatment options for various diseases through innovative approaches.
Latest Patents
Sae Hyung Lee holds 1 patent for his invention titled "PEGylated interferon-beta variant." This invention provides a PEGylated IFN-β variant and a composition aimed at preventing or treating hyperproliferative diseases, inflammatory diseases, autoimmune diseases, or viral infectious diseases. The PEGylated IFN-β variant demonstrates excellent anti-viral efficacy, immune regulatory function, and anti-cell growth efficacy due to its superior pharmacokinetic properties compared to native and non-PEGylated IFN-β variants. This innovation offers significant patient convenience in administration and a notable increase in half-life in blood over existing interferon formulations.
Career Highlights
Sae Hyung Lee is currently associated with Abion Inc., where he continues to advance his research and development efforts. His work has positioned him as a key figure in the biotechnology sector, contributing to the development of effective treatments for complex diseases.
Collaborations
He has collaborated with notable colleagues, including Young-Kee Shin and Young-Deug Kim, to further enhance the impact of his research and innovations.
Conclusion
Sae Hyung Lee's contributions to biotechnology, particularly through his PEGylated interferon-beta variant, highlight his commitment to improving therapeutic options for patients. His innovative work continues to pave the way for advancements in medical treatments.